The cancer clinical trials newsletter
Clinical Trials News is a free email digest from the GeneAnalyses team. Each weekday it summarises newly posted and newly updated oncology and life-sciences trials in plain language, and a weekly edition steps back to the trends. Every item links to its ClinicalTrials.gov record, regulator document or primary publication so you can check the design yourself.
Subscribe to Clinical Trials News
A daily, plain-language digest of new oncology and life-sciences clinical trials, with a weekly deep-dive roundup — every update linked to its trial registry or primary source.
Open the newsletterWhat you get
- A daily plain-language brief of new and changed trials, grouped by indication and modality
- A weekly roundup of the readouts, approvals and pipeline shifts that mattered
- Direct links to the trial registry, label or paper behind every claim
- No stock tips, no hype — development activity is not the same as clinical benefit
Recent editions
Full archiveCan a new prostate cancer drug beat the old standard pill?
Here's what happened in cancer research today, in plain English. The biggest story involves a new kind of prostate cancer treatment being tested against the pills doctors currently reach for first. There's also news on lung cancer, breast cancer monitoring, an…
GSK's B7-H3 ADC challenges prostate cancer's default therapy
By the numbers Events covered: 27 · Dominant indication: — Dominant modality: Supportive/behavioral care · Biggest round: — GSK swings a B7-H3 ADC at prostate cancer's default therapy GlaxoSmithKline [B7-H3 antibody-drug conjugate (risvutatug rezetecan) | Meta…
A Cancer Drug Trio That Might Skip the Transplant
Here's what happened in cancer research today, in plain English. Most of what came through the pipeline was routine, small studies on surgery techniques and anesthesia choices, but one stood out: a New York cancer center just opened a trial testing whether a n…
Sonrotoclax Tests Frontline MCL Without a Transplant
By the numbers Events covered: 18 · Dominant indication: — · Dominant modality: Behavioral/supportive-care & combination therapy (tied) · Biggest round: — Sonrotoclax Tests Frontline MCL Without a Transplant Memorial Sloan Kettering Cancer Center [Triplet comb…
Breast Cancer Trials Lead a Pipeline-Heavy, Readout-Light Week
By the numbers — week ending 31 August 2026 Trial events tracked: 137 · Dominant indication: Breast cancer, 13.1% share · Dominant modality: Small molecule inhibitors, 19.0% share · Phase 3+ readouts: 1 · Total funding: — This week's 137 tracked trial events s…
Breast Cancer Leads a Slow Week for Phase 3 Readouts
By the numbers -- week ending 29 August 2026 Trial events tracked: 161 · Dominant indication: Breast cancer, 13% share · Dominant modality: Checkpoint-inhibitor combinations, 7% share · Phase 3+ readouts: 1 · Total funding: — (not tracked this week) This week'…
Can a New Antibody Drug Keep Ovarian Cancer From Coming Back?
Here's what happened in cancer research today, in plain English. A well-known drugmaker started a large trial for a new kind of ovarian cancer drug, another company is testing whether an approved myeloma treatment can help a rare blood disorder, and a small bi…
Daiichi's Next ADC Takes Aim at Ovarian Maintenance
By the numbers Events covered: 29 · Dominant indication: — Dominant modality: Immunotherapy combinations · Biggest round: — Daiichi's Next ADC Takes Aim at Ovarian Maintenance Daiichi Sankyo [CDH6-targeted antibody-drug conjugate | Ovarian, primary peritoneal…
An existing leukemia drug faces its hardest test yet
Here's what happened in cancer research today, in plain English. Most of the day's news was quiet, but one story stands out: a fresh look at whether an existing leukemia drug can outdo its toughest rival in the patients who need it most. An existing leukemia d…
Asciminib takes on ponatinib in T315I-mutant CML
By the numbers Events covered: 29 · Dominant indication: — · Dominant modality: — · Biggest round: — Asciminib heads back into ponatinib's territory Thomas Ernst, PD Dr. med. [STAMP inhibitor | Chronic myeloid leukemia, T315I mutation | Phase 2] Asciminib alre…
Can a lung cancer drug actually reach a brain tumor?
Here is what happened in cancer research today, in plain English. Most of it is early and small, which is normal: most cancer trials start this way, quietly, long before anyone knows if the idea will work. A lung cancer drug is about to try something new: reac…
Tarlatamab's next test: can it cross into glioma?
By the numbers Events covered: 22 · Dominant indication: — · Dominant modality: Supportive-care/behavioral (5 of 22) · Biggest round: — Tarlatamab's next test: can it cross into glioma? Vall d'Hebron Institute of Oncology [DLL3-targeted bispecific T-cell engag…
Understand the biology behind the headlines
The digest tells you what changed; these source-linked explainers tell you why the target matters.
Clinical Trials News is an educational research digest, not investment, diagnosis or treatment advice. Early data can change with follow-up and regulatory status can change. Issue list refreshed 4 September 2026.
Read Clinical Trials News on Substack